

UPMC Hillman Cancer Center, Partner with University of Pittsburgh Cancer Institute, and the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences Presents:

## **A Comprehensive Review of the Most Important Presentations from the 2020 San Antonio Breast Cancer Symposium**

---

**Date:** Friday, February 12, 2021

**Time:** Registration begins at 8:00 am  
Conference: 8:30 am to 1:30 pm

**Location:** Conference will be held virtually via MS TEAMS

### **Course Directors:**

#### **Dhaval Mehta, MD**

Clinical Assistant Professor of Medicine  
UPMC Hillman Cancer Center, Monroeville

#### **Shannon Puhalla, MD**

Assistant Professor of Medicine  
University of Pittsburgh School of Medicine  
UPMC Hillman Cancer Center  
UPMC Passavant  
Magee-Women's Hospital of UPMC

### **Program Goal:**

This program will provide a comprehensive review of the most important presentations from the 2020 San Antonio Breast Cancer Symposium.

### **Target Audience:**

Physicians, researchers, advanced practice providers, nurses, and other health care professionals who work with individuals with breast cancer.

### **Course Objectives:**

Upon completion of this program, attendees will be able to:

- Identify the most up to date findings in breast cancer clinical and translational research.
- Incorporate research findings to appropriately manage patients with breast cancer.
- Demonstrate understanding of the scientific findings in breast cancer research by demonstrating competence in the clinical setting.

### **Course Handouts:**

Presentations will **not** be printed. A copy of presentation slides can be accessed via UPMC MyCloud. Instructions on how to access program slides will be emailed to the email address that was provided during online registration.

### **Accreditation and credit designation**

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 4.75 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### Other Healthcare Professionals

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

### **We gratefully acknowledge support from the following for this activity:**

#### Exhibitors:

AstraZeneca – ADC Franchise, Enhertu

AstraZeneca – DDR

Lilly Oncology

Seagen

Novartis

Eisai

Merck

Puma Biotechnology

Daiichi Sankyo

Genentech – member of the Roche group

Agendia Inc.

## Agenda

<b>8:30 am</b>	Welcome- Shannon Puhalla, MD; Dr Dhaval Mehta, MD
<b>8:35 am</b>	Breast Surgery Updates – Emilia Diego, MD
<b>8:55 am</b>	Pathology Update – Beth Clark, MD
<b>9:10 am</b>	Radiology Updates – Austin Vargo, MD
<b>9:25 am</b>	Questions and Answers
<b>9:35 am</b>	Adjuvant Options in High Risk ER+ Breast Cancer – Priya Rastogi, MD
<b>9:55 am</b>	Genomics Testing Updates in ER+ Breast Cancer – Adam Brufsky, MD, PhD
<b>10:15 am</b>	Questions and Answers
<b>10:30 am</b>	Survivorship Update – Josie van Londen, MD, MSc
<b>10:40 am</b>	Basic Science – ESR1 hotspot mutations – Steffi Oesterreich, PhD
<b>10:55 am</b>	Questions and Answers
<b>11:05 am</b>	Break/ Vendor Breakout Sessions
<b>11:20 am</b>	Immunotherapy in Triple Negative Breast Cancer – Leisha Emens, MD, PhD
<b>11:40 am</b>	Chemotherapy in ER+ Breast Cancer – Vikram Gorantla, MD
<b>12:00 pm</b>	Updates in Her2neu + Breast Cancer – Kit Lu, MD
<b>12:20 pm</b>	Questions and Answers
<b>12:30 pm</b>	Basic Science- Brain Mets/Breast Cancer – Adrian Lee, PhD
<b>12:40 pm</b>	Novel Agents/NSABP trials – Shannon Huggins-Puhalla, MD
<b>1:00 pm</b>	Monday Morning/COVID 19/UPMC community trials – Dhaval Mehta, MD; Terry Evans, MD
<b>1:20 pm</b>	Final Comments – Dhaval Mehta, MD, and Shannon Puhalla, MD
<b>1: 30 pm</b>	Adjournment

***Dr Shannon Puhalla and Dr Dhaval Mehta will moderate question and answer sections.***

## Faculty

<p><i>Adam Brufsky, MD, PhD, FACP</i>  <i>Professor of Medicine</i>  <i>University of Pittsburgh School of Medicine</i>  <i>Associate Division Chief Division of Hematology Oncology</i>  <i>University of Pittsburgh Medicine</i>  <i>Medical Director, Magee Women's Cancer Program</i>  <i>UPMC Hillman Cancer Center</i>  <i>Co-Director, Comprehensive Breast Cancer Center</i>  <i>Magee-Women's Hospital of UPMC</i></p> <p><i>Beth Clark, MD</i>  <i>Faculty-Clinician, Physician</i>  <i>UPP17 Pathology Magee</i>  <i>Magee-Womens Hospital of UPMC</i></p> <p><i>Emilia Diego, MD</i>  <i>Assistant Professor</i>  <i>University of Pittsburgh School of Medicine</i>  <i>Magee-Women's Hospital of UPMC</i></p> <p><i>Leisha A. Emens, MD, PhD</i>  <i>Professor of Medicine</i>  <i>UPMC Hillman Cancer Center/Women's Hospital</i>  <i>Cancer Research Center</i>  <i>Co-Leader, Hillman Cancer Immunology/Immunotherapy Program</i></p> <p><i>Terry L. Evans, MD, FACP</i>  <i>Clinical Assistant Professor of Medicine</i>  <i>University of Pittsburgh School of Medicine</i>  <i>Medical Director of the Arnold Palmer Cancer Center</i></p> <p><i>Vikram Gorantla, MD</i>  <i>Medical Oncologist</i>  <i>UPMC Hillman Cancer Center</i></p> <p><i>Adrian V. Lee, PhD</i>  <i>Pittsburgh Foundation Endowed Chair in Precision Medicine</i>  <i>Professor of Pharmacology &amp; Chemical Biology</i>  <i>Director, Institute for Precision Medicine</i>  <i>UPMC Hillman Cancer Center</i></p> <p><i>Kit Lu, MD</i>  <i>Physician, Medical Oncology</i>  <i>PHHAR-HCC Pinnacle</i></p>	<p><i>Dhaval Mehta, MD</i>  <i>Clinical Assistant Professor</i>  <i>University of Pittsburgh School of Medicine</i>  <i>UPMC Hillman Cancer Center,</i>  <i>Monroeville</i></p> <p><i>Steffi Oesterreich</i>  <i>Faculty, Health Science Schools</i></p> <p><i>Priya Rastogi, MD</i>  <i>Senior Associate Medical Director</i>  <i>NSABP Medical Affairs</i>  <i>Associate Professor of Medicine</i>  <i>University of Pittsburgh School of Medicine</i>  <i>UPMC Hillman Cancer Center</i></p> <p><i>Shannon Puhalla, MD</i>  <i>Assistant Professor of Medicine</i>  <i>University of Pittsburgh School of Medicine</i>  <i>UPMC Hillman Cancer Center</i>  <i>UPMC Passavant</i>  <i>Magee-Women's Hospital of UPMC</i></p> <p><i>G. van Londen, MD, MSc</i>  <i>Associate Professor,</i>  <i>University of Pittsburgh School of Medicine, Department of Medicine,</i>  <i>Divisions of Hematology-Oncology and Geriatric Medicine</i>  <i>ABIM certified in Medical Oncology and Geriatric Medicine</i>  <i>Director of UPMC's CancerLiveWell Survivorship Program and Breast Geriatric Cancer Clinic.</i></p> <p><i>John Austin Vargo, MD</i>  <i>Assistant Professor of Radiation Oncology</i>  <i>Regional Medical Director, Central Region</i>  <i>Magee Women's Hospital of UPMC</i></p>
--	---

### Faculty Disclosure:

All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:

- Adam Brufsky, MD, PhD – Consultant: Puma, Seattle Genetics, Daiichi, Roche, AstraZeneca, Pfizer, Novartis
- Emilia Diego, MD – Other: DSMB Xoft, Inc.
- John Austin Vargo, MD – Other: Clinical Pathways, Elsevier
- Kit Lu, MD – CE Speakers' Bureau: AstraZeneca, Daiichi Sankyo, Seattle Genetics
- Leisha A. Emens, MD, PhD – Global Clinical Trial Steering Committees/Data Safety Monitoring Boards: Co-Chair Impassion130 Steering Committee (Genentech/Roche), Chair KATE2 Steering Committee (Genentech/Roche), Chair TRIO-025 DSMB (Trio/Syndax), Ambiance Trial Steering Committee Member. Consulting/Advisory Board/Honoraria: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Meyer Squibb, Celgene, Chugia, CytomX, eTheRNA, Genentech, Gilead, GPCR Therapeutics, Gritstone, JKTG Foundation, Medimmune, Molecuvax, MacroGenics, Novartis, Peregrine, Replimune, Roche, Shionogi, Silverback, Syndax, Vaccinex; Grant/Research Support: Aduro Biotech, AstraZeneca, Bolt, Breast Cancer Research Foundation, Bristol Meyer Squibb, Corvus, Department of Defense, EMD Serono, Genentech, HertiX, Inc., Maxcyte, Merck, National Cancer Institute, NSABP Foundation, Roche, Silverback/AACR, Su2C, Tempest, Translational Breast Cancer Research Consortium, Royalties: Aduro IND Licensing/vaccine
- Shannon Puhalla, MD – Grant/Research Support: AbbVie, Pfizer, Lilly, Novartis, Incyte, Covariance-Bayer, AstraZeneca; Consultant: AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Esai, nanostring
- Vikram Gorantla, MD – Consultant: IntegraConnect
- Priya Rastogi, MD – Consultant: Advisory Board for Genentech; Other: Travel & Accommodations Lilly, Genentech, AstraZeneca
- Steffi Oesterreich, PhD – Grant/Research Support: AstraZeneca, Illumina, H3 Biomedicine, Blueprint Medicine, Zentalis, Advisory Board NSABP; NCI, BCRF, Susan G Komen, MBCN, Breast Cancer Alliance; Other: NASBP, McGill University, Georgetown.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

Questions? Call UPMC Hillman Cancer Center Professional and Patient Education at 412-623-3661